Cynata Therapeutics Pty Ltd
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company developing disruptive regenerative medicine products. We are the leading company worldwide in the development of iPSC-derived cell therapies. By using our…
Overview
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company developing disruptive regenerative medicine products. We are the leading company worldwide in the development of iPSC-derived cell therapies.
By using our unique manufacturing platform, Cymerus™, which enables us to economically produce therapeutic mesenchymal stem cells (MSCs) at scale with a consistent quality, we are able to overcome the inherent challenges in first generation methods of manufacturing MSCs for therapeutic use.
We have generated compelling preclinical data in models of a range of different therapeutic indications. We have completed a Phase I clinical study with our lead MSC product candidate, CYP-001, in the treatment of acute steroid-resistant graft-versus-host-disease (aGvHD), a disease with devastating results. Having met all endpoints, the trial results demonstrated excellent safety and efficacy data, which allowed us to progress to an ongoing Phase II study in the USA, Australia, and Europe. We have partnered with University of Sydney in a randomised, double-blind, placebo-controlled phase 3 study in osteoarthritis and this this trial has completed recruitment of over 300 patients.